4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Several other research firms also recently issued reports on FDMT. Royal Bank of Canada dropped their price target on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Chardan Capital dropped their price target on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. The Goldman Sachs Group dropped their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Bank of America dropped their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. Finally, Barclays dropped their price target on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Trading Down 3.1%

Shares of FDMT stock opened at $3.49 on Friday. The company’s fifty day simple moving average is $3.25 and its 200-day simple moving average is $4.88. 4D Molecular Therapeutics has a 52 week low of $2.24 and a 52 week high of $28.93. The company has a market cap of $161.67 million, a PE ratio of -1.22 and a beta of 2.87.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). Equities research analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of FDMT. Peapod Lane Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at about $806,000. Rhumbline Advisers boosted its holdings in shares of 4D Molecular Therapeutics by 5.3% in the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after buying an additional 3,675 shares during the period. Proficio Capital Partners LLC boosted its holdings in shares of 4D Molecular Therapeutics by 100.0% in the 4th quarter. Proficio Capital Partners LLC now owns 20,000 shares of the company’s stock valued at $111,000 after buying an additional 10,000 shares during the period. M&T Bank Corp boosted its holdings in shares of 4D Molecular Therapeutics by 98.9% in the 4th quarter. M&T Bank Corp now owns 37,487 shares of the company’s stock valued at $209,000 after buying an additional 18,639 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at about $629,000. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.